Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis

Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis

BackgroundFinerenone and sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to improve cardiovascular and renal outcomes in patients with type 2 diabetes mellitus (T2DM), while the relative efficacy has not been determined.MethodsThe databases of PubMed, Embase and Cochrane were sear...

Full description

Bibliographic Details
Main Authors:	Xuefeng Li, Hongli Wu, Huifang Peng, Hongwei Jiang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Endocrinology
Subjects:	finerenone (BAY 94-8862) SGLT2i T2DM cardiovascular and renal outcomes network meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2022.1078686/full

Similar Items

Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease
by: Yaning Zheng, et al.
Published: (2022-01-01)

Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
by: Yaofu Zhang, et al.
Published: (2022-11-01)

Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
by: Ruolin Lv, et al.
Published: (2023-02-01)

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
by: Li-Min Zhao, et al.
Published: (2022-01-01)

Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials
by: Yue Du, et al.
Published: (2024-01-01)

Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease
by: Yaofu Zhang, et al.
Published: (2022-10-01)

Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis
by: Samit Ghosal, et al.
Published: (2023-01-01)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
by: Dimitrios Patoulias, et al.
Published: (2022-02-01)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014-01-01)

Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis
by: Xia Gu, et al.
Published: (2024-01-01)

Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes: The FIDELIO-DKD Subgroup from China
by: Haitao Zhang, et al.
Published: (2023-08-01)

Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
by: Bin Zhou, et al.
Published: (2022-05-01)

SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?
by: Dimitrios Patoulias
Published: (2018-04-01)

Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin
by: Panagiotis Theofilis, et al.
Published: (2022-10-01)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
by: Dong-Lim Kim, et al.
Published: (2023-02-01)

Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus
by: Tao Jin, et al.
Published: (2023-04-01)

Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis
by: Deep Dutta, et al.
Published: (2022-01-01)

Cardiorenal benefits of finerenone: protecting kidney and heart
by: José R. González-Juanatey, et al.
Published: (2023-12-01)

Potassium management with finerenone: Practical aspects
by: Christoph Wanner, et al.
Published: (2022-11-01)

Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus
by: Melpomeni Peppa, et al.
Published: (2023-10-01)

Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives
by: Shaikh A, et al.
Published: (2022-07-01)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
by: Jennifer Matthews, et al.
Published: (2023-09-01)

The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
by: Michail Koutentakis, et al.
Published: (2023-11-01)

Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone
by: Nicholas Chiu, et al.
Published: (2022-04-01)

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
by: Sara W. Quist, et al.
Published: (2023-11-01)

Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis
by: Api Chewcharat, et al.
Published: (2020-11-01)

Sex-dependent effects of finerenone on hemostasis in normoglycemic and streptozotocin-induced diabetic mice
by: Bielicka Natalia, et al.
Published: (2023-12-01)

SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis
by: Mainak Banerjee, et al.
Published: (2023-03-01)

SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules
by: Yajiao Wang, et al.
Published: (2023-01-01)

Administration of finerenone in chronic kidney disease
by: Mohsen Akhavan Sepahi, et al.
Published: (2023-01-01)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
by: Yuta Suzuki, et al.
Published: (2022-05-01)

Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
by: Ning Li, et al.
Published: (2021-11-01)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
by: Peter Kolkhof, et al.
Published: (2022-08-01)

Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials
by: Yu Jiang, et al.
Published: (2022-03-01)

Association between SGLT2 Inhibitors and Cardiac Rehabilitation Outcomes in Patients with Cardiovascular Disease and Type 2 Diabetes Mellitus
by: Ayuko Kashima, et al.
Published: (2022-10-01)

Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials
by: John M. Flack, et al.
Published: (2023-12-01)

Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study
by: David Vizcaya, et al.
Published: (2023-06-01)

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
by: Takayuki Yamada, et al.
Published: (2021-01-01)

Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Ming-Zhu Zhang, et al.
Published: (2022-02-01)

Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis
by: Sylvia E. Rosas, et al.
Published: (2023-10-01)